- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
NEW YORK — Drug maker Merz Pharmaceuticals is suing Par Pharmaceutical over the latter's attempt to market a generic drug for cerebral palsy patients, according to published reports.
Bloomberg reported that Merz sued Par in the U.S. District Court for the District of Delaware after Par attempted to apply for Food and Drug Administration approval for a generic version of Cuvposa (glycopyrrolate) oral solution, used to treat severe drooling in cerebral palsy patients.
The drug received FDA approval this year, and Merz bought rights to the drug in August.